Company Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.
The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Javier Szwarcberg |
Contact Details
Address: 611 Gateway Boulevard, Suite 740 South San Francisco, California 94080 United States | |
| Phone | 415 655 4168 |
| Website | sprucebiosciences.com |
Stock Details
| Ticker Symbol | SPRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001683553 |
| CUSIP Number | 85209E109 |
| ISIN Number | US85209E1091 |
| Employer ID | 81-2154263 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer and Director |
| Michael G. Grey | Executive Chairman |
| Samir M. Gharib CPA, M.B.A. | President and Chief Financial Officer |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer |
| P. J. Ramtin | Senior Vice President of Business Operations |
| Heidi Petersen M.P.H. | Senior Vice President of Regulatory and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |